Lu-177 FAP-targeted therapy
FAP (Fibroblast Activation Protein) is a marker found on cancer-associated fibroblasts — the supportive cells around tumors — in many solid cancers. Targeting FAP allows therapy to reach cancers that don't have their own unique surface markers.
What it could help
- Pancreatic cancer (very aggressive, few targeted options today)
- Sarcomas (rare cancers of bone and soft tissue)
- Breast cancer (specific subtypes)
- Cholangiocarcinoma (bile duct cancer)
- Other solid tumors with FAP expression
Where it is in development
FAP-targeted Lu-177 therapies (such as Lu-177 FAPI-46 and related compounds) are in phase 1 and 2 trials in multiple centers globally. Indian centers, including a few in across India have begun participating. Early data is promising but data is still limited — definitive efficacy hasn't been established yet.
Lu-177 DOTATATE therapy off-label for meningiomas
Some grade 1 and grade 2 meningiomas (slow-growing brain tumors arising from the membranes around the brain) express somatostatin receptors at high levels. This means they can sometimes be treated with the same Lu-177 DOTATATE therapy drug approved for NETs.
This is “off-label” use — meaning the drug is approved for NETs but is being used here for a different cancer based on clinical evidence and physician judgment. Several published series suggest meaningful tumor control in selected patients, particularly when surgery and radiation are no longer options.
Pediatric trials
Neuroblastoma — a cancer that primarily affects children — has been a target of Lu-177 therapy research using a targeting molecule called I-131 MIBG (and now newer Lu-177 variants). Pediatric protocols are highly specialized and available at a small number of centers globally. Indian participation is growing.
Combination and sequencing strategies
A major area of research isn't a new drug, but smarter use of existing drugs:
- Combining Lu-177 PSMA therapy with radium-223 in bone-predominant prostate cancer
- Combining Lu-177 DOTATATE therapy with chemotherapy in higher-grade NETs
- Combining Lutetium therapy with immunotherapy checkpoints (e.g., pembrolizumab)
- Adding new oral hormonal agents to Lutetium therapy in prostate cancer
Actinium-225: the next generation
Ac-225 is a different radioactive isotope — an alpha-emitter rather than Lu-177's beta-emitter. Alpha particles travel even shorter distances and deliver much higher localized energy. For patients whose cancer has stopped responding to Lu-177 therapy, Ac-225 paired with the same PSMA or DOTATATE targeting molecules has shown remarkable activity in early trials.
Ac-225 therapies are still investigational and access is limited — but they represent one of the most-watched areas of theranostics research today.
How to access an emerging Lutetium therapy
Through a clinical trial
The standard path is to enrol in a registered clinical trial. India has growing participation in international Lu-177 trials, particularly through major cancer centers across multiple Indian cities.
- Search trials at ClinicalTrials.gov using terms like “Lu-177 FAP” or “Lu-177 meningioma”
- Ask your oncologist or contact a major center directly about open trials
- A patient navigator can help you find the right trial for your situation
Through compassionate use / off-label
For very specific situations, off-label use of Lu-177 DOTATATE therapy (for meningiomas, for example) is sometimes available at experienced centers. This is a case-by-case clinical decision and not insurance-covered in most countries.
Frequently asked questions
Should I wait for the latest therapy or start with what's available?
If you're eligible for an approved therapy (Lu-177 PSMA therapy or Lu-177 DOTATATE therapy) and your oncologist recommends it, the case for waiting is usually weak. Approved therapies have strong evidence. Investigational therapies may or may not work. A common pattern is approved therapy first, then trial participation if the approved option stops working.
Are clinical trials safe?
Trials are heavily regulated to protect participants. They include detailed informed consent, ongoing safety monitoring, and an independent oversight board with the power to stop the trial if problems emerge. The bigger risk in trials is usually that the therapy doesn't work, not that it causes severe harm — though specific risks vary by trial.
Will I have to pay to be in a clinical trial?
Trial drug and trial-related procedures are usually provided free of charge. You're often responsible for standard-of-care costs (your routine appointments, standard scans). Travel costs are sometimes reimbursed by the sponsor. Confirm specifics before enrolling.
Can international patients join Indian trials?
Yes, in many cases. Some trials are open to international participants; some are restricted to local residents. Practical considerations include visa duration, follow-up requirements, and language. A navigator can help you assess which trials are accessible.